Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight

Morgan Stanley analyst Michael Ulz downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Equal-Weight to Underweight.

Morgan Stanley analyst Michael Ulz downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Equal-Weight to Underweight.

Total
0
Shares
Related Posts